Companies › OncoC4
4 active drug programs in 7 registered trials: 5 Phase 1, 1 Phase 3, 1 Phase 2; Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ONC-392 (Gotistobart) anti-CTLA4 monoclonal antibody | CTLA4 | Phase 3 | Non Small Cell Lung Cancer; Ovarian Cancer; Metastatic Castration-resistant Prostate Cancer | Nov 2026 |
| AI-081 Bispecific antibody targeting PD-1 and VEGF | PDCD1, VEGFA | Phase 1 | Advanced Solid Tumor | Jun 2027 |
| ONC-783 Bispecific antibody targeting CD24 and CD3 | CD24, CD3 | Phase 1 | Advanced Solid Tumor | Aug 2027 |
| ONC-841 Anti-SIGLEC10 antibody with IgG4 Fc domain | SIGLEC10 | Phase 1 | Advanced Solid Tumor | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05682443 | ONC-392 (Gotistobart) | Phase 1 | Metastatic Castration-resistant Prostate Cancer | Oncology | Nov 2026 |
| NCT04140526 | ONC-392 (Gotistobart) | Phase 1 | Non Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT06635785 | AI-081 | Phase 1 | Advanced Solid Tumor | Oncology | Jun 2027 |
| NCT07408258 | ONC-783 | Phase 1 | Advanced Solid Tumor | Oncology | Aug 2027 |
| NCT05446298 | ONC-392 (Gotistobart) | Phase 2 | Ovarian Cancer | Oncology | Aug 2027 |
| NCT05671510 | ONC-392 (Gotistobart) | Phase 3 | Non Small Cell Lung Cancer | Oncology | Aug 2027 |
| NCT06352359 | ONC-841 | Phase 1 | Advanced Solid Tumor | Oncology | Sep 2027 |
Agenus AskGene Pharma MacroGenics CrystalGenomics Lepu Biopharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.